Enhanced serum concentrations of Ara-C using suppositories containing tetrahydrouridine as a deamination inhibitor of Ara-C.
Rectal bioavailability of Ara-C (serum AUC 4 h: 65 micrograms h-1 ml-1) administered in a suppository formulation containing tetrahydrouridine (a deamination inhibitor) and sodium salicylate (an adjuvant) to dogs was better than that from a suppository formulation without tetrahydrouridine (serum AUC 4 h: 18 micrograms h-1 ml-1).
Liversidge
G G
GG
Nishihata
T
T
Engle
K K
KK
Higuchi
T
T
D000818:Animals; D001086:Arabinofuranosyluracil / Q000097:blood; D001682:Biological Availability; D003561:Cytarabine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000097:blood*; D003641:Deamination; D004285:Dogs; D007700:Kinetics; D012459:Salicylates / Q000494:pharmacology; D020156:Salicylic Acid; D013488:Suppositories; D013767:Tetrahydrouridine / Q000494:pharmacology*; D014529:Uridine / Q000031:analogs & derivatives*
D012459:Salicylates; D013488:Suppositories; D003561:Cytarabine; D013767:Tetrahydrouridine; D001086:Arabinofuranosyluracil; D020156:Salicylic Acid; D014529:Uridine